EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Protara Therapeutics's Enterprise Value is $9.72 Mil.
Protara Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-35.09 Mil. Therefore, Protara Therapeutics's EV-to-FCF for today is -0.28.
The historical rank and industry rank for Protara Therapeutics's EV-to-FCF or its related term are showing as below:
TARA'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.77 Med: 0 Max: 1.91
Current: -0.28
During the past 6 years, the highest EV-to-FCF of Protara Therapeutics was 1.91. The lowest was -0.77. And the median was 0.00.
TARA's EV-to-FCF is ranked worse than 100% of 377
companies
in the Biotechnology industry
Industry Median: 8.21
vs TARA: -0.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Protara Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Protara Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Protara Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protara Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protara Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Protara Therapeutics's EV-to-FCF falls into.
Protara Therapeutics's current Enterprise Value is $9.72 Mil.
Protara Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Protara Therapeutics's PE Ratio for today is calculated as:
Protara Therapeutics's share price for today is $2.80.
Protara Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Protara Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Protara Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Protara Therapeutics (Protara Therapeutics) Business Description
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TARA has been successfully added to your 